The Unified Patent Court (UPC) has ruled European Patent No. EP 4 051 265 invalid and dismissed Enanta Pharmaceuticals' infringement lawsuit against Pfizer Inc. regarding the sale of Paxlovid in 18 EU member states. The decision concludes a hearing held on September 29, 2026, where Pfizer counterclaimed for revocation of the patent. This ruling eliminates Enanta's intellectual property rights to nirmatrelvir in the affected jurisdictions and removes potential litigation damages or licensing revenue from this specific legal action. Enanta Pharmaceuticals operates as a biopharmaceutical company focused on developing treatments for infectious diseases.
